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NOTE 
PATENTING THE DIAGNOSIS OF A 
DISEASE: THE SCOPE OF 
PATENTABLE SUBJECT MATTER 
BASED ON LABCORP V. 
METABOLITE LABS 
INTRODUCTION: THE STRUGGLE TO DEFINE THE SCOPE OF PATENTABLE 
SUBJECT MATTER 
Determining the limits of what should be patentable subject matter 
is a fundamental issue of patent law. Congress defined patentable 
subject matter in 35 U.s.C. § 101 as a "new and useful process, machine, 
manufacture, or composition of matter, or any new and useful 
improvement thereof."t The United States Supreme Court in Diamond v. 
Chakrabarty noted that 35 U.S.c. § 101 should be construed broadly to 
promote innovation and account for unforeseeable changes in 
technology.2 However, the Court also noted that 35 U.S.c. § 101 cannot 
be construed so broadly as to allow patenting of "[t]he laws of nature, 
physical phenomena, and abstract ideas.,,3 
Currently, a method of diagnosing a disease can be broadly claimed 
in a patent.4 In Metabolite Laboratories, Inc. v. Laboratory Corp. of 
America Holdings, the United States Court of Appeals for the Federal 
135 V.S.C.A. § 101 (Westlaw 2007). 
2 See Diamond v. Chakrabarty, 447 V.S. 303, 316 (1980). The Court construed § 101 to 
encompass microorganisms. [d. at 318. 
3 [d. at 309. 
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Circuit recently upheld the patentability of a method-of-diagnosis claim 
for a vitamin B deficiency.5 The method claim correlated an elevated 
level of total homocysteine to a vitamin B deficiency.6 This method 
claim was not limited to a particular procedure for performing the 
measurement. 7 In fact, the method claim was arguably construed to 
cover all future improvements to the measurement method so long as the 
resulting measurement was used for the determination of a vitamin B 
deficiency. 8 
The United States Supreme Court initially granted certiorari in 
Metabolite Labs to decide whether the method-of-diagnosis claim was 
patentable. 9 Later, the Court dismissed certiorari as improvidently 
granted. \0 This Note asserts that the Court should have adjudicated the 
case because there is a great need to clarify what is patentable subject 
matter for method claims that do not entail a physical transformation of 
matter, particularly in view of the seeming inconsistency between 
Diamond v. Diehr and State Street Bank & Trust Co. v. Signature 
Financial Group. I I There is strong public interest in clarifying 35 U.S.C. 
§ 101, as evidenced by an unusually large number of amici briefs in 
LabCorp.12 Twenty amici briefs were submitted from a diverse group of 
entities such as the American Association of Retired People,13 American 
Medical Association,14 American Express,15 IBM,16 Bear Stearns & 
5 [d. at 1368. 
6 [d. at 1358-59. 
7 See id. 
S See Brief of the American Clinical Laboratory Association as Amicus Curiae in Support of 
Petitioner at 13, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 
04-067). 
9 Petition for a Writ of Certiorari, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 
S. Ct. 2921 (2006) (No. 04-067), available at 2004 WL 2505526; Lab. Corp. of Am. Holdings v. 
Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 543 (2005) (limiting grant of certiorari to issue three 
only). 
IO Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 2921, 2922 
(2006). 
II See id. at 2928 (Breyer, J., dissenting). Compare Diamond v. Diehr, 450 U.S. 175, 192 
(1980) (holding that a method claim that includes a physical transformation of matter is patentable) 
with State Street Bank & Trust Co. v. Signature Fin. Group, 149 F.3d 1368, 1373 (Fed. Cir. 1998) 
(holding that a method claim that produces '''a useful, concrete, and tangible result'" is patentable). 
12 LabCorp, 126 S. Ct. at 2926 (Breyer, J., dissenting). 
13 Brief Amicus Curiae of AARP in Support of Petitioner, Lab. Corp. of Am. Holdings v. 
Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067). 
14 Brief for the American Medical Association, the American College of Medical Genetics, 
the American College of Obstetricians and Gynecologists, the Association for Molecular Pathology, 
the Association of American Medical Colleges, and the College of American Pathologists as Amici 
Curiae in Support of Petitioner, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 
2921 (2006) (No. 04-067 ). 
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Lehman Brothers, 17 Affymetrix, 18 Perlegen,19 American Clinical 
Laboratory Association,20 and the Computer & Communications Industry 
Association. 21 
This Note additionally asserts that a patent claiming a method of 
diagnosing a disease that consists of essentially two steps-(1) a medical 
measurement that is not specific to a particular method, and (2) a 
correlation step that uses the medical measurement for identifying a 
disease state-should not be patentable subject matter under 35 U.S.C. § 
101.22 As currently construed by the court of appeals in Metabolite Labs, 
a method-of-diagnosis claim can cover all improvements to the 
measurement method that will likely be invented in the future. 23 The 
method claim in Metabolite Labs essentially grants a monopoly over a 
natural phenomenon, and allowing such monopolies will impede 
progress in developing improved medical measurements and thus deprive 
the public of potential advancements in healthcare. 24 
Part I will provide a brief background in patent law, describe the 
15 Brief of Amicus Curiae American Express Company in Support of Neither Party, Lab. 
Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067). 
16 Brief of International Business Machines Corporation as Amicus Curiae in Support of 
Neither Party, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 
04-067). 
17 Brief of Financial Services Industry Amici Curiae in Support of Reversal, 126 S. Ct. 2921 
(2006) (No. 04-067). 
18 Brief Amicus Curiae of Affymetrix, Inc. and Professor John H. Barton in Support of 
Petitioner, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-
067). 
19 Brief for Amicus Curiae Per1egen Sciences, Inc. and Mohr, David Ventures in Support of 
Respondents, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-
067). 
20 Brief of the American Clinical Laboratory Association as Amicus Curiae in Support of 
Petitioner, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-
067). 
21 Brief for Amicus Curiae Computer & Communications Industry Association in Support of 
Petitioner, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-
067). 
22 See Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 2921, 
2927 (2006) (Breyer, J., dissenting). 
23 See Brief of the American Clinical Laboratory Association as Amicus Curiae in Support of 
Petitioner at 13, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 
04-067); Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1362-64 (Fed. Cir. 
2004). Abbott Laboratories later developed an improved assay that was held to be an infringing 
assay. Brief for Respondents at 7, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 
2921 (2006) (No. 04-067), available at 2006 WL 303905. 
24 See Michael Meehan, The Handiwork of Nature: Patentable Subject Matter and 
Laboratory Corporation v. Metabolite Labs, 16 ALB. L.J. SCI. & TECH 311, 317 (2006); see also 
Brooks Gifford, Paper, Oh, Diehr: The CAFe'S Troubling Patent Eligibility Jurisprudence as 
Applied in Metabolite Laboratories v. LabCorp, 25 BIOTECHNOLOGY L. REP. 129, 129 (2006). 
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current interpretation of 35 U.S.C. § 101 for method claims, and 
summarize the facts and procedural history of the suit against LabCorp.25 
Part II will analyze why the Federal Circuit's interpretation of a method 
of diagnosing a vitamin B deficiency was too broad and will inhibit 
future research needed for better healthcare. 26 Part III will conclude that 
the Supreme Court should have reversed the Federal Circuit's decision in 
Metabolite Labs.27 
I. BACKGROUND 
To enhance the discussion of LabCorp, infra, a review of basic 
patent law will be provided. Next, the current interpretation of 35 U.S.C. 
§ 10 1 for software method claims will be summarized. Issues that the 
biotech industry is facing due to the current application of 35 U.S.C. § 
101 also will be presented. Finally, the facts regarding the discovery of 
the method of diagnosing a vitamin B deficiency and the procedural 
history of the infringement suit against LabCorp will be set forth. 
A. PATENT LAW BASICS 
Article I, section 8, clause 8, of the United States Constitution gave 
Congress the right to regulate patents for promoting "the Progress of 
Science and the useful ArtS.,,28 A person who invents a "new and useful 
process, machine, manufacture, or composition of matter" may apply for 
and obtain a patent.29 An inventor may apply for a patent by submitting 
an application to the United States Patent and Trademark Office 
(USPTO).3o If a patent examiner at the USPTO finds that the invention 
is novel and non-obvious based on the prior art,3l a patent will be 
granted. 32 The inventor will then receive a limited monopoly on his or 
her invention for a term beginning on the date on which the patent issues 
25 See infra notes 28-161 and accompanying text. 
26 See infra notes 162-312 and accompanying text 
27 See infra notes 313-317 and accompanying text. 
28 U.S. CONST art. I, § 8, c1. 8. 
29 35 U.S.C.A. § 101 (Westlaw 2007). 
30 35 U.S.C.A. § III (WestIaw 2007); see also U.S. Patent & Trademark Office, Patent, How 
to Get a, http://www.uspto.gov/web/patents!howtopat.htm (last visited Mar. 18, 2007). 
31 "Prior art" a body of knowledge from the beginning of time that may include public 
knowledge, public use, a patent, a printed publication, or a public sale. See 35 U.S.C. § 102 
(WestIaw 2007); Walter J. Blenko, Jr., Considering What Constitutes Prior Art in the United States, 
43 JOM 45 (1991), available at http://www.tms.orglpubsljournals/JOM/matterslmatters-9106.html. 
32 35 U.S.C.A. §§ 102, 103 (Westlaw 2007). 
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and ending twenty years from the date the application was filed. 33 In 
exchange for the limited monopoly, the invention will be free for the 
public to use once the patent expires. 34 Further, the invention will 
usually be published eighteen months after filing of the application so 
that the public can improve upon the invention or design around the 
invention. 35 Thus, patent law must provide '''a careful balance'" 
between the benefits to the inventor in the form of a limited monopoly, 
and the utility to the public in the form of public disclosure, because the 
patent system is the "very lifeblood of a competitive economy.,,36 
A patent provides a patentee the right to exclude others from 
infringing the patent. 37 There are two types of infringement, direct and 
indirect. 38 Direct infringement occurs when one makes, uses, offers to 
sell, or sells any patented invention within the United States and without 
authority. 39 To directly infringe a patent, the accused infringer must 
perform each and every element of a patent claim.40 The intent of the 
infringer does not matter when evaluating direct infringement,41 in 
contrast to indirect infringement.42 
One form of indirect infringement is inducement to infringe, which 
33 35 U.S.C.A. § 154(a)(2) (Westlaw 2007). 
34 See Bonito Boats v. Thunder Craft Boats. 489 U.S. 141.152 (1989). 
35 35 U.S.C.A. § 122 (Westlaw 2007). 
36 See Brief for Amicus Curiae Affymetrix. Inc. and Professor John H. Barton in Support of 
Petitioner at 12. Lab. Corp. of Am. Holdings v. Metabolite Labs .• Inc .• 126 S. Ct. 2921 (2006) (No. 
04-067) (citing Bonito Boats. 489 U.S. at (46). 
37 "[Wlhoever without authority makes. uses. offers to sell. or sells any patented invention. 
within the United States or imports into the United States any patented invention during the term of 
the patent therefor. infringes the patent." 35 U.S.c.A. § 271(a) (Westlaw 2007) (direct 
infringement). "Whoever actively induces infringement of a patent shall be liable as an infringer." 
U.S.C. § 271(b) (Westlaw 2007) (inducement to infringe). "Whoever offers to sell or sells within 
the United States or imports into the United States a component of a patented machine. manufacture. 
combination or composition. or a material or apparatus for use in practicing a patented process. 
constituting a material part of the invention. knowing the same to be especially made or especially 
adapted for use in an infringement of such patent. and not a staple article or commodity of commerce 
suitable for substantial noninfringing use. shall be liable as a contributory infringer." 35 U.S.C.A.. 
271(c) (Westlaw 2007) (contributory infringement). A further discussion of 35 U.S.C.A. § 271(c) is 
beyond the scope of this Note. 
38 35 U.S.C.A. § 271 (a).(b) (Westlaw 2007). 
39 35 U.S.C.A. § 271 (a) (Westlaw 2007). 
40 Warner-Jenkinson Co .• Inc. v. Hilton Davis Chemical Co .• 520 U.S. 17. 29 (1997); see also 
Prouty v. Ruggles. 41 U.S. 336. 341 (1842); Kristin E. Gerdelman. Comment. Subsequent 
Performance of Process Steps by Different Entities: Time to Close Another Loophole in U.S. Patent 
Law. 53 EMORY LJ. 1987. 1994-95 (2004). 
41 Warner-Jenkinson. 520 U.S. at 35. 
42 Kristin E. Gerdelman. Comment. Subsequent Performance of Process Steps by Different 
Entities: Time to Close Another Loophole in U.S. Patent Law. 53 EMORY LJ. 1987. 1994 (2004) 
(citing Water Techs. Corp. v. Calco. Ltd .• 850 F.2d 660. 668 (Fed. Cir. (988». 
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occurs when a party actively induces or encourages infringement by 
another party.43 As a threshold consideration, it must be determined 
whether someone directly infringed the patent.44 Next, there must be 
evidence that the alleged indirectly infringing party encouraged another 
to perform the infringing act. 45 Either direct or circumstantial evidence 
may be used for establishing liability for inducement to infringe.46 An 
example of circumstantial evidence could be an advertising document 
that encourages one to infringe a patent. 47 Lastly, unlike direct 
infringement, the party allegedly actively inducing another to infringe 
must intend to do SO.48 
B. HISTORY OF UNITED STATES SUPREME COURT DECISIONS 
DEFINING PATENTABLE SUBJECT MATIER UNDER 35 U.S.c. § 101 
FOR SOFTW ARE-RELATED METHOD CLAIMS 
Starting around the 1970s, there was an explosion in the 
development of computers and software technology that continues to this 
day.49 There are "[c]lose to one hundred thousand software or software-
related patents [that] are now in force in the United States, and several 
thousand more are being issued every year.,,50 In a trio of cases, the 
United States Supreme Court defined the patentability requirements for 
software-related method5! claims under 35 U.S.c. § 101.52 The most 
recent of these decisions for defining patentable subject matter was 
decided over 25 years ago. 53 In Diamond v. Diehr, the Court held that a 
method claim that includes a physical transformation of matter is 
patentable subject matter under 35 U.S.c. § 101.54 However, the Court 
indicated that a method claim not involving a physical transformation of 
43 35 U.S.C.A. § 271(b) (Westlaw 2007). 
44 See Joy Techs., Inc. v. F1akt, Inc., 6 F.3d 770, 774 (Fed. Cir. 1993). 
45 1d. 
46 Moleculon Research Corp. v. CBS, Inc., 793 F.2d 1261, 1272 (Fed. Cir. 1986) (citing 
Michalic v. Cleveland Tankers, Inc., 364 U.S. 325, 330 (1960)). 
47 Kristin E. Gerdelman, supra note 42, at 200 I. 
48 
Water Techs. Corp., 850 F.2d at 660; Gerdelman, supra note 42, at 2000. 
49 See Julie E. Cohen & Mark A. Lemley, Patent Scope and Innovation in the Software 
Industry, 89 CAL. L. REv. I, 11-14 (2001). 
50/d. at II. 
51 A method claim and a process claim have the same meaning and are used interchangeably. 
35 U.S.C.A. § 100(b) (Westlaw 2007). 
52 Diamond v. Diehr, 450 U.S. 175, 192 (1980); Parker v. Flook, 437 U.S. 584, 590-94 
(1978); Gottschalk v. Benson, 409 U.S. 63, 70-71 (1972). 
53 Diehr, 450 U.S. at 192. 
54 See id. 
6
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matter may still be patentable. 55 The Court broadly stated that a method 
claim is patentable subject matter if it "perform[ed] a function which the 
patent laws were designed to protect.,,56 After the holding in Diehr, there 
remained substantial uncertainty in defining patentable subject matter 
under 35 U.S.c. § 101 for process claims that do not entail a physical 
transformation of matter.57 
There were several cases in the 1980s and 1990s in which the 
Federal Circuit and its predecessor, the United States Court of Customs 
and Patent Appeals, struggled to apply the holding of Diehr to determine 
whether software process claims should be patentable subject matter 35 
U.s.c. § 101.58 In an attempt to clarify the United States Supreme Court 
holding in Diehr,59 the Federal Circuit in State Street Bank seemingly 
eliminated the physical-transformation requirement.60 The Federal 
Circuit held that a method claim would be patentable subject matter so 
long as it provided "a useful, concrete, and tangible result.,,61 The rule in 
State Street Bank has arguably increased the scope of patentable subject 
matter to include abstract ideas or mental thoughts. 62 As a result, since 
State Street Bank, the United States Patent and Trademark Office has 
issued an increasing number of software-method patents, especially 
business-method patents.63 The rapid increase in issued method patents 
has generated harsh criticism of the rule developed in State Street Bank.64 
C. ISSUES FACING THE BIOTECH INDUSTRY UNDER THE CURRENT 
INTERPRETATION OF 35 U.S.c. § 101 
Similar to the computer software industry, the biotechnology 
55 See id. 
56 Id. 
57 See Cathy E. Cretsinger, I. Intellectual Property: B. Patent: 4. Patentability: a) Computer 
Software: AT&T Corp. v. Excel Communications, Inc., 15 BERKELEY TECH. LJ. 165, 168 (2000). 
58 See In re Alappat, 33 F.3d 1526, 1542-44 (Fed. Cir. 1994); Arrhythmia Research Tech., 
Inc. v. Corazonix Corp., 958 F.2d 1053, 1056-60 (Fed. Cir. 1992); In re Meyer, 688 F.2d 789, 794-
96 (C.c.P.A. 1982); In re Abele, 684 F.2d 902, 907-908 (C.c.P.A. 1982). 
59 Diehr, 450 U.S. at 192. 
60 See State Street Bank & Trust Co. v. Signature Fin. Group, 149 F.3d 1368, 1373 (Fed. Cir. 
1998). 
61 Id. 
62 See Cretsinger, supra note 57 at 177-80. 
63 Brief for Amicus Curiae Computer & Communications Industry Association in Support of 
Petitioner at 14-15, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) 
(No. 04-067), available at 
http://www.ccianet.org/modules/patentPDFs/CCIALabCorpMeritsAmicus[04-607J.pdf. 
64 See Robert P. Merges, As Many as Six Impossible Patents Before Breakfast: Property 
Rights for Business Concepts and Patent System Reform, 14 BERKELEY TECH. LJ. 577, 587 (1999). 
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industry has experienced explosive growth and technological 
advancement over the last thirty years.65 One area of recent growth in 
biotechnology has been in the medical diagnostic field, involving the 
development of new blood tests (i.e., assays) for diagnosing a disease or 
predicting the likelihood of developing a disease in the future. 66 For 
example, such a test can measure a concentration of a particular chemical 
or the presence of a genetic marker. 67 
The medical diagnostics industry is very important to the United 
States economy in regard to sales and the creation of jobs,68 and thus 
significant benefits would flow from a clarification of 35 U.S.c. § 101. 
The diagnostic portion of the biotech industry generated approximately 
forty-six billion dollars in revenue and 187,500 jobs in the year 2004 
alone. 69 The United States government has a significant interest in 
tailoring patent law to provide an incentive for innovation, by promoting 
commerce through the award of limited monopolies.70 However, to 
promote innovation through patents, the United States government must 
exercise the right balance by granting a limited monopoly only when the 
inventor provides the public a substantive advance in science and the 
useful arts.71 
Broad-based method patents can be used to enjoin the performance 
of diagnosing a disease.72 In essence, allowing a broad-based method 
65 See John M. Golden, Biotechnology, Technology Policy, and Patentability: Natural 
Products and Invention in the American System, 50 EMORY LJ. 101,113 (2001). 
66 See Genetics: The Future of Medicine, NIH Publication No. 00-4873, at 9, available at 
http://www.genome.govlPageslEducationKitlimageslnhgri.pdf (last visited Dec. 16,2006); Brief for 
Amicus Curiae Perlegen Sciences, Inc. and Mohr, David Ventures in Support of Respondents at 21, 
Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067); Brief for 
Amicus Curiae Affymetrix, Inc. and Professor John H. Barton in Support of Petitioner at 12, Lab. 
Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067) (noting 
growth in genome analysis). 
67 See Genetics: The Future of Medicine, NIH Publication No. 00-4873, at 9, available at 
hnp:llwww.genome.govlPages/EducationKitlimageslnhgri.pdf (last visited Mar. 18,2007); Brief for 
Amicus Curiae Perlegen Sciences, Inc. and Mohr, David Ventures in Support of Respondents at 12-
14, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067) 
(describing diagnostic tests for prostate cancer, AIDS, ovarian cancer, and neoplastic tissue). 
68 Biotechnology Industry Organization (2005). Biotechnology Industry Facts; and Burrill 
and Company (2005). Biotech 2006: What's Really Going to Happen. Gene Acres, Sept. 25, 
available at http://www.cccbiotech.org/pdfltrainingneeds21stcentury.pdf. 
69 Id. 
70 See Bonito Boats v. Thunder Craft Boats, 489 U.S. 141,146 (1989). 
71 See id. 
72 See Brief of the American Clinical Laboratory Association as Amicus Curiae in Support of 
Petitioner at 8-13, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) 
(No. 04-067). 
8
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claim amounts to granting a patent on the practice of medicine. 73 
Examples of diseases covered by method claims are prostate cancer, 74 
HIV/AIDS/5 breast cancer,76 ovarian cancer,77 and vitamin B 
deficiency.78 In the practice of medicine, a physician will routinely order 
a blood test to measure particular chemical or genetic information, 
correlate the results to the presence or absence of a disease, and inform 
the patient of the result. 79 Thus, the standard practice of medicine for 
diagnosing a disease may be enjoined through broad-based method 
patents. 
Under one interpretation, the medical measurement step in 
Metabolite Labs does not include a physical transformation of matter, 
and thus it should not be patentable subject matter based on the U.S. 
Supreme Court holding in Diehr. 80 However, the method-of-diagnosis 
claim can be construed to provide a useful, concrete, and tangible result 
and therefore could be patentable subject matter based on the Federal 
Circuit holding in State Street Bank.81 This inconsistency illustrates the 
apparent dichotomy in standards for defining patentable subject matter 
for process claims that has existed since the ruling in State Street Bank.82 
73 See Brief Amicus Curiae of AARP In Support of Petitioner at 17, Lab. Corp. of Am. 
Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067). 
74 U.S. Patent No. 5,840,501 (issued Nov. 24, 1998) (quoted in Brief for Amicus Curiae 
Perlegen Sciences, Inc. and Mohr, David Ventures in Support of Respondents at 12, Lab. Corp. of 
Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067)). 
75 U.S. Patent No. RE38,352 (issued Dec. 16, 2003) (quoted in Brief for Amicus Curiae 
Perlegen Sciences, Inc. and Mohr, David Ventures in Support of Respondents at 12, Lab. Corp. of 
Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067)). 
76 U.S. Patent No. 5,709,999 (issued Jan. 20, 1998) (quoted in Brief for Amicus Curiae 
Affymetrix, Inc. and Professor John H. Barton in Support of Petitioner at 19, Lab. Corp. of Am. 
Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067). 
77 U.S. Patent No. 4,968,603 (issued Nov. 6, 1990) (quoted in Brief for Amicus Curiae 
Perlegen Sciences, Inc. and Mohr, David Ventures in Support of Respondents at 13, Lab. Corp. of 
Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067)). 
78 U.S. Patent No. 4,940,658 (issued July 10, 1990). 
79 See Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1364 (Fed. Cir. 
2004). 
80 See Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 2921, 
2927 (2006) (Breyer, J., dissenting). 
81 See State Street Bank & Trust Co. v. Signature Fin. Group, 149 F.3d 1368, 1373 (Fed. Cir. 
1998). 
82 Compare Diamond v. Diehr, 450 U.S. 175, 192 (1980) with State Street Bank, 149 F.3d at 
1373. 
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D. FACTS AND PROCEDURAL HISTORY OF LABCORP 
1. Discovery of the Method 
In Metabolite Labs, a trio of medical-school professors from the 
University of Colorado and Columbia University discovered a method of 
diagnosing a vitamin B deficiency.83 The discovered method involved a 
correlation between the concentration of total homocysteine in blood and 
a vitamin B deficiency. 84 The term "total homocysteine" represents the 
aggregate concentration of four different forms of homocysteine. 85 
Homocysteine is an amino acid that can be found in the human body. 86 
Amino acids may be used to build proteins that exist in nature. 87 
Vitamin B is an essential chemical necessary for the health and 
development of humans.88 Vitamin B complex is a group of vitamins 
including BI (thiamin), B2 (riboflavin), B6 (pyridoxine), niacin, 
pantothenic acid, folate, and BI2 (cobalamin).89 Although there are 
several different vitamin B complexes, the specific type of vitamin B 
deficiency referred to in this Note concerns only cobalamin (vitamin Bu) 
and folate. Thus, all references to vitamin B hereinafter will refer only to 
cobalamin and folate. 
A vitamin B deficiency may cause one or more serious illnesses 
including those that relate to cognitive dysfunction, birth defects, and 
cancer.90 If the vitamin B deficiency is detected early, a physician can 
prescribe a vitamin supplement to improve the patient's health and 
overcome the vitamin B deficiency.91 However, if the diagnosis is not 
timely, a patient can suffer serious illness or death.92 Thus, although the 
83 Brieffor Respondents at 1-2, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. 
Ct. 2921 (2006) (No. 04-067), available at 2006 VlL 303905. 
84 Id. at 2. For more information on homocysteine, see generally American Heart 
Association, What is Homocysteine?, http://www.americanheart.org!presenter.jhtml?identifier=535 
(last visited Sept. 16, 2006). 
85 Brief for Respondents at 3, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. 
Ct. 2921 (2006) (No. 04-067), available at 2006 WL 303905. 
86 Brief for Petitioner at 2, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 
2921 (2006) (No. 04-067), available at 2005 WL 3543099. 
87 FuNDAMENTALS OF CLINICAL CHEMISTRY, 291 (Norbert W. Tietz ed., 3d ed. 1987). 
88 Id. at 497. 
89 1d. at 497-512, 815-18. 
90 Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1358 (Fed. Cir. 
2004). 
91 1d. 
92 See Brief for Respondents at I, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 
S. Ct. 2921 (2006) (No. 04-067), available at 2006 WL 303905. 
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new method was initially repudiated by the medical community, it 
provided physicians with a useful and previously unknown way of 
detecting a vitamin B deficiency that eventually became well-accepted 
and frequently referenced.93 
Traditionally, a vitamin B deficiency was initially diagnosed by 
observing anemia and enlarged red blood cells in a patient's blood.94 
Mter the initial diagnosis, the deficiency was verified by measuring a 
low concentration of vitamin B in the patient's blood.95 Research studies 
had demonstrated that a vitamin B deficiency was not detected in a 
significant number of people using the traditional test.96 Thus, a large 
number of patients in need of immediate treatment were left untreated 
because they were not diagnosed by the traditional test. 97 
In contrast, the new total homocysteine test was much more 
effective because of a much lower percentage of false negative results 
(i.e., the proportion of patients with a vitamin B deficiency that were not 
diagnosed).98 Therefore, the total homocysteine measurement was a 
major breakthrough enabling the early diagnosis of a vitamin B 
deficiency. Without the new test, millions of people with a vitamin B 
deficiency would not be properly diagnosed, causing them to potentially 
suffer a serious illness.99 
2. Licensing of the Idea 
In addition to discovering the correlation between the total 
homocysteine concentration and a deficiency in vitamin B, the medical-
school professors invented new and better assays for measuring total 
homocysteine in blood. 100 Through their research, the universities that 
employed the professors were able to obtain U.S. Patent No. 4,940,658 
("'658 patent"). The '658 patent claimed a method of measuring the 
total homocysteine concentration and a method of diagnosing a patient 
93 Id. at 4-5. 
94 Id. at 2. Anemia is a condition that consists of a relatively low concentration of red cells in 
blood. FUNDAMENTALS OF CLINICAL CHEMISTR Y, 789 (Norbert W. Tietz ed., 3d ed. 1987). 
95 Brief for Respondents at 2, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 s. 
Ct. 2921 (2006) (No. 04-067), available at 2006 WL 303905. 
96 See id. at 4. 
97 1d. 
98 See id. at 2 n.2. 
99 See id. at 4. 
lOOMetabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1358 (Fed. Cir. 
2004). An assay is an analysis is to determine the presence, absence, or quantity of one or more 
components. Merriam-Webster Online Dictionary, http://www.m-w.comldictionary/assay (last 
visited Feb. 25, 2007). 
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with a vitamin B deficiency. 101 Both Columbia University and the 
University of Colorado assigned the patent to a predecessor of 
Competitive Technologies, Inc. 102 In turn, Competitive Technologies 
granted a patent license to Metabolite Laboratories, Inc. ("Metabolite 
Labs"). 103 Metabolite Labs sublicensed the patent to Roche Biomedical 
Laboratories to perform the total homocysteine assay.l04 Later, Roche 
Biomedical Laboratories became Laboratory Corporation of America 
("LabCorp,,).105 
LabCorp performed the assay and paid royalties to both Metabolite 
Labs and Competitive Technologies for six years.l06 In 1998, Abbott 
Laboratories developed an improved total homocysteine assay. 107 
LabCorp adopted the Abbott assay but did not pay royalties to 
Metabolite Labs and Competitive Technologies when using the Abbott 
assay. 108 However, LabCorp did continue to pay royalties when it used 
the Metabolite Labs version. I09 LabCorp thought that royalty payments 
were not necessary when using the Abbott version of the total 
homocysteine assay.11O However, Metabolite Labs and Competitive 
Technologies sued LabCorp for patent infringement and breach of 
license because they asserted that the '658 patent covered any assay for 
measuring total homocysteine, including the Abbott assay. II I 
101 Metabolite Labs, 370 F.3d at 1358. 
102 Brief for Respondents at 6, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. 
Ct. 2921 (2006) (No. 04-067), available at 2006 WL 303905. Competitive Technologies is a 
company that specializes in licensing technological developments to industry from universities. Id. 
103 Brief for Respondents at 6, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. 
Ct. 2921 (2006) (No. 04-067), available at 2006 WL 303905. The University of Colorado 
established Metabolite Labs so that the inventors could develop the total homocysteine assay into a 
format available to physicians. Id. 
104 Metabolite Labs, 370 F.3d at 1359. 
105 Id. 
106 Brief for Respondents at 7, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. 
Ct. 2921 (2006) (No. 04-067), available at 2006 WL 303905. A physician would order the assay 
and arrange to have the blood sample sent to LabCorp for performing the measurement of total 
homocysteine. Id. at 7 n.3. 
107 Brief for Respondents at 7, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. 
Ct. 2921 (2006) (No. 04-067), available at 2006 WL 303905. 
108 [d. at 8. 
1(J9 Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 2921, 2923 
(2006) (Breyer, J., dissenting). 
110 See Brief for Respondents at 8, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 
S. Ct. 2921 (2006) (No. 04-067), available at 2006 WL 303905. 
III Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1358-59 (Fed. Cir. 
2004). 
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3. District Court Decision 
At the district-court level, the jury found that LabCorp had infringed 
the patent and breached the license agreement. 112 LabCorp was ordered 
to pay nearly 3.7 million dollars in damages for breach of contract and 2 
million dollars for willful infringement of the patent. 113 
One of the main issues argued in the district court was whether 
LabCorp infringed Claim 13 of the '658 patent. 114 Whether LabCorp 
infringed rested on how the district court construed Claim 13: 15 Claim 
13 describes "a method for detecting a deficiency of cobalamin or folate 
in warm-blooded animals comprising the steps of: assaying a body fluid 
for an elevated level of total homocysteine; and correlating an elevated 
level of total homocysteine in said body fluid with a deficiency of 
cobalamin or folate.,,1l6 
During the Markman claim-construction hearing, I 17 LabCorp 
wanted the court to construe "correlating" as establishing a mutual or 
reciprocal relationship with "an elevated level of homocysteine." lIS 
LabCorp also asserted that the correlating step must include a vitamin B 
deficiency that causes either a hematologic or neuropsychotic 
abnormality.119 The district court adopted only the initial portion of 
LabCorp's construction, holding that "correlate" means "'to establish a 
mutual or reciprocal relation of an elevated level of homocysteine," "but 
declined to 'include a[ny] reference to [a] hematologic or neuropsychotic 
abnormality.''' 120 The trial judge found that construing the correlation 
step to include evidence of a hematologic or neuropsychotic disorder 
would "impermissibly import[] a limitation from the specification" into 
the claim. 121 LabCorp appealed to the Federal Circuit. 122 
112 [d. Interestingly, Abbott Laboratories, who manufactured and sold the total homocysteine 
assay kit used by LabCorp, was not charged with infringement in this suit. There are no facts 
discussed in the case on whether Abbott Laboratories induced infringement. 
113 Metabolite Labs, 370 F.3d at 1359. 
114 [d. at 1361. 
115 See id. at 1360. 
116 U.S. Patent No. 4,940,658 (issued July 10, 1990) (emphasis added). 
117 A Markman hearing is where the judge can construe the meaning of the language used in a 
patent claim. See Markman v. Westview Instruments, Inc., 52 F.3d 967, 987 (Fed. Cir. 1995). 
118 Metabolite Labs, 370 F.3d at 1361. 
119 !d. 
120 [d. (quoting LabCorp's Markman brief). 
121 Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1361 (Fed. Cir. 
2004) (finding a hematologic or neuropsychotic disorder that is described in the written description 
of the patent should not be required as a necessary result of the correlation step described in the 
claim). A specification is a written description of the invention. 35 U.S.c. § 112 (Westlaw 2007). 
122 Metabolite Labs, 370 F.3d at 1358. 
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4. Federal Circuit's Affirmance of District Court 
On appeal, LabCorp argued that the district court erred in 
construing the term "correlating" too broadly.123 LabCorp argued again 
that the term "correlating" should be limited to a vitamin B deficiency 
that '''causes a hematologic or neuropsychiatric abnormality. ",124 
However, the Federal Circuit affirmed the district court's construction. 125 
The court then turned to the issue of direct infringement. 126 Based 
on the district court's claim interpretation, the jury verdict had held 
LabCorp liable for indirect infringement, but the jury also found that 
physicians directly infringed the patent because they ordered the assay 
and correlated the results. 127 
As evidence to support the direct infringement, LabCorp's 
Discipline Director testified at trial that physicians performed the 
correlation step after receiving the results from LabCorp.128 As further 
evidence that physicians performed this step, an inventor of the '658 
patent "testified that it would be malpractice for a [physician] to receive 
a total homocysteine assay without determining cobalamin/folate 
deficiency." 129 The court noted that "'[c]ircumstantial evidence is not 
only sufficient, but may also be more certain, satisfying and persuasive 
than direct evidence. ",130 Therefore, the Federal Circuit found sufficient 
evidence to support the jury finding that physicians directly infringed 
because they would always be ethically compelled to think about the 
correlation after ordering a total homocysteine assay.131 
After physicians were established as direct infringers, the Federal 
Circuit went on to analyze whether LabCorp had induced physicians to 
infringe Claim 13. 132 LabCorp had published articles targeted to 
physicians to inform them that elevated concentrations of total 
homocysteine could be correlated to a vitamin B deficiency.133 In 
addition, the articles stated that such a deficiency could be treated 
123 See id. at 1361. 
124 1d. 





130 1d. at 1365 (citing Moleculon Research Corp. v. CBS, Inc., 793 F.2d 1261, 1272 (Fed. Cir. 
1986». 
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through vitamin supplements. 134 The Federal Circuit interpreted the 
publications as evidence that LabCorp promoted the use of total 
homocysteine assays for detecting a vitamin B deficiency.135 The 
Federal Circuit therefore affIrmed the jury's finding that LabCorp had 
induced infringement of Claim 13. 136 
5. Denial of Certiorari by the United States Supreme Court 
Mter losing on appeal, LabCorp filed a petition for a writ 
of certiorari to the United States Supreme Court. 137 The Court initially 
granted certiorari on only one issue: whether a method patent that directs 
a party to simply correlate test results can validly "claim a monopoly 
over a basic" scientific principle such that any physician necessarily 
infringes the patent by merely thinking about the relationship after 
looking at test results. 138 Although certiorari was initially granted, it was 
subsequently dismissed as having been improvidently granted. 139 
In dissenting from the dismissal of the petition for the writ of 
certiorari, Justice Breyer acknowledged that there was a procedural 
problem with the writ in that "LabCorp did not refer in the lower courts 
to" an issue with 35 U.S.c. § 101.140 Although the Court "might benefit 
from the views of the Federal Circuit" 141 on the 35 U.S.c. § 101 issue, 
Justice Breyer asserted that the Court nevertheless had the power to 
adjudicate an issue that was not properly raised in the lower court, citing 
United States v. Williams. 142 
Because the issue was "fully briefed and argued by the parties, the 
Government, and the [twenty] amici," he argued that the case could be 




137 Petition for a Writ of Certiorari, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 
S. Ct. 2921 (2006) (No. 04-067), available at 2004 WL 2505526. 
138 [d.; Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 543 
(2005) (limiting grant of certiorari to issue three only). 
139 Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (Lab Corp), 126 S. Ct. 2921, 2921 
(2006). 
140 Id. at 2925 (Breyer, J., dissenting). 
141 [d. at 2925 (Breyer, J., dissenting) (citing United States v. Bestfoods, 524 U.S. 51, 72-73 
(1998)). 
142 [d. at 2925-26 (Breyer, J., dissenting) (citing United States v. Williams, 504 U.S. 36, 40 
(1992)). The traditional rule is that the Supreme Court should not grant certiorari when the argument 
was not pressed by the litigant or passed on by the court below. Williams, 504 U.S. at 41. The 
Williams Court noted that the rule "operate[dj in the disjunctive, permitting review of an issue not 
pressed so long as it has been passed upon." [d. 
15
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the lower courts. 143 Justice Breyer conceded that it would have been 
better for the issue to have been considered by the Federal Circuit, but 
found "the extra time, cost, and uncertainty that further proceedings 
would engender [ were] not worth the potential benefit." 144 
Justice Breyer emphasized that a timely clarification of 35 U.S.C § 
101 was important because it would benefit medical researchers, 
physicians, and the patients who depend on proper healthcare. 145 He 
noted that the Federal Circuit's current interpretation for method-of-
diagnosis claims, such as Claim 13 of the '658 patent, "may inhibit 
[physicians] from using their best medical judgment." 146 As a potentially 
undesirable result of the Federal Circuit's interpretation, Justice Breyer 
noted that physicians may be forced to spend time licensing patents and 
searching for potentially infringing patents instead of focusing their 
efforts on helping the public through the practice of medicine. 147 
Additionally, Justice Breyer discussed whether Claim 13 was 
patentable subject matter under 35 U.S.c. § 101.148 He stated that "the 
correlation between homocysteine· and vitamin deficiency set forth in 
Claim 13 is a 'natural phenomenon.",149 As support, he noted that 
Metabolite Labs had practically conceded that the correlation step 
between total homocysteine and a deficiency in vitamin B standing alone 
is a natural phenomenon. 150 
Metabolite Labs, however, had asserted that Claim 13 was valid 
because considered as a whole, it "entails a physical transformation of 
matter" (the alteration of a blood sample) and "produces a useful, 
concrete, and tangible result" (the diagnosis of a vitamin B 
deficiency). 151 Justice Breyer rejected the first argument because Claim 
13 does not describe an assay that transforms blood. 152 Claim 13 simply 
describes the use of any assay for measuring total homocysteine, which 
includes unpatented methods of measuring homocysteine. 153 He 
interpreted Claim 13 to "instruct[] [a] user to (1) obtain test results and 
143 LabCorp, 126 S. Ct. at 2926 (Breyer, J., dissenting). 
144 [d. 
145 See Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 2921, 
2928 (2006) (Breyer, J., dissenting). 
146 [d. 
147 [d. at 2928-29. 
148 [d. at 2927. 
149 [d. 
150 [d. 
151 [d. (quoting Brief for Respondent at 33, 36, Lab. Corp. of Am. Holdings v. Metabolite 
Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067)). 
152 LabCorp, 126 S. Ct. at 2927 (Breyer, J., dissenting). 
153 [d. 
16
Golden Gate University Law Review, Vol. 38, Iss. 1 [2007], Art. 5
http://digitalcommons.law.ggu.edu/ggulrev/vol38/iss1/5
2007] PATENTING A DIAGNOSIS 155 
(2) think about them.,,154 He rejected Metabolite Labs' argument as not 
persuasive, because virtually any law of nature applied to "any useful 
purpose could involve the use of empirical information obtained through 
an unpatented means that might have involved transforming matter.,,155 
Justice Breyer also rejected Metabolite Labs' second argument that 
a process is patentable if it produces a "'useful, concrete, and tangible 
result. '" 156 He noted that the Court itself had not held that all processes 
that have a useful, concrete, and tangible result were patentable subject 
matter, and "if taken literally [that] statement would cover instances 
where [the] Court ha[d] held the contrary.,,157 Justice Breyer cited 
several cases in which the Court had held process claims unpatentable, 
even though they produced a useful, concrete, and tangible result. 158 
Justice Breyer emphasized that he would reject Claim 13 as outside 
the scope of patentable subject matter under 35 U.S.C. § 101, because it 
"amount[ed] to a simple natural correlation, i.e., a 'natural 
phenomenon. ",159 In this case, he interpreted the process claim as "an 
instruction to read some numbers in light of medical knowledge." 160 
Justice Breyer concluded that Claim 13 was unpatentable because the 
correlation step was a "natural phenomenon" and there was nothing in 
Claim 13 that "add[ed] anything more of significance." 161 
154 [d. 
155 [d. 
156 [d. at 2928. 
157 [d. 
158 [d. (citations omitted). In 0 'Reilly v. Morse, the Court invalidated a process claim that 
transmitted messages over long distances, which was certainly a useful, concrete, and tangible result. 
See O'Reilly v. Morse, 56 U.s. 62, 112-13 (1854). In Flook, the Court invalidated a process claim 
that triggered alarm limits for a catalytic converter, which was also a useful, concrete, and tangible 
result. Parker v. Flook, 437 U.S. 584, 594 (1978). In Gottschalk, the Court invalidated a process 
claim that converted decimal figures into binary figures, which would arguably be a useful, concrete, 
and tangible result for improving the wiring system of a computer. Gottschalk v. Benson, 409 U.S. 
63,73 (1972). 
159 Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 2921, 2928 




Ohara: Patenting a Diagnosis
Published by GGU Law Digital Commons, 2007
156 GOLDEN GATE UNIVERSITY LAW REVIEW [Vol. 38 
II. ANALYSIS 
A. THE METHOD IN CLAIM 13 Is NOT PATENTABLE UNDER UNITED 
STATES SUPREME COURT PRECEDENT 
1. Claim 13 Can Be Construed as a Mathematical Formula that Wholly 
Preempts the Fieldfor Measuring Total Homocysteine 
"[O]ne may not patent an idea.,,162 The United States Supreme 
Court held in Gottschalk v. Benson that a process claim directed to a 
mathematical formula would in effect be a patent on an idea if the 
process claim wholly preempts the use of the mathematical formula. 163 
In Gottschalk, the mathematical formula converted binary-coded decimal 
numerals into pure binary numerals. l64 The alleged invention in 
Gottschalk was that a binary number can be transformed into a different 
state using a mathematical formula. 165 The claim was broadly drafted 
such that all unknown and future uses of the mathematical formula 
would infringe the patent. 166 
The correlation step in Metabolite Labs is analogous to the 
mathematical formula in Gottschalk. Claim 13 of the '658 patent may be 
construed to have a mathematical formula in the correlation step.167 The 
correlation step essentially consists of a physician comparing a total 
homocysteine concentration to a threshold value. 168 If the total 
homocysteine concentration is greater than the threshold, then the patient 
is diagnosed with a vitamin B deficiency.169 The correlation step can be 
translated to the following mathematical formula: if H > E, then there is a 
vitamin B deficiency, where H = total homocysteine concentration, and E 
= elevated level of total homocysteine. Construing the correlation step as 
a mathematical formula does not change the meaning of the claim in any 
162 Gottschalk, 409 U.S. at 71; accord Diamond v. Diehr, 450 U.S. 175, 185 (l980). 
163 Gottschalk, 409 U.S. at 71-72. 
164 Id. at 64 
165 Id. Conversion of decimal numbers to binary numbers may be useful "within a computer's 
wiring system." Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 2921, 
2928 (2006) (Breyer, J., dissenting). 
166 See Gottschalk, 409 U.S. at 68. 
167 See In re Application of Richman, 563 F.2d 1026, 1030 (C.C.P.A. 1977) (noting that 
words can essentially mean the same thing as a mathematical formula). 
168 See Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1364, 1367 
(Fed. Cir. 2004) (citing the '658 patent at col. 9, II 26-29). 
169 See id. 
18
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way, but it does illustrate the application to the holding in Gottschalk. 170 
The mathematical formula is a compulsory step that is performed in 
the physician's mind after ordering a total homocysteine assay, because 
"it would be malpractice for a [physician] to receive a total homocysteine 
assay without determining a vitamin B deficiency." 171 Therefore, a 
physician necessarily uses the mathematical formula when ordering a 
total homocysteine assay and infringes Claim 13. Conversely, the 
mathematical formula cannot be used without performing an assay for 
total homocysteine concentration because the concentration (i.e., H) is 
part of the mathematical formula. Accordingly, all uses of the 
mathematical formula would infringe Claim 13 of the '658 patent. 172 
Claim 13 of '658 patent should be invalidated because it wholly 
preempts the use of the mathematical formula as defined here in the 
correlation step, which violates the rule in Gottschalk. 173 
2. The Mathematical Formula in Claim 13 Patents a Law of Nature 
"[T]he discovery of a law of nature cannot be patented.,,174 The 
United States Supreme Court, in Parker v. Flook, noted that "natural 
phenomena ... are not the kind of 'discoveries'" that were meant to be 
patented under 35 U.S.C. § 101.175 The Court defined a scientific 
principle or a natural phenomenon to be a relationship that has always 
existed even before its discovery.176 The Court used Newton's law of 
gravity between two bodies as an example of a natural phenomenon that 
has always existed, even before its discovery by Newton. 177 The Court 
emphasized that mere recognition of an existing phenomenon does not 
170 Gottschalk, 409 U.S. at 71-72. 
171 Metabolite Labs, 370 F.3d at 1364. 
172 See Brief for Amicus Curiae Affymetrix, Inc. and Professor John H. Barton in Support of 
Petitioner at 11-12, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. CI. 2921 (2006) 
(No. 04-067) ("[TJhe natural relationship between elevated amino acid levels and vitamin deficiency 
has been 'pre-empted' by the patent claim."); Gottschalk, 409 U.S. at 71-72. 
173 See Brief for Amicus Curiae Affymetrix, Inc. and Professor John H. Barton in Support of 
Petitioner at 11-12, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. CI. 2921 (2006) 
(No. 04-067); Gottschalk, 409 U.S. at 71-72. One may argue that Claim 13 does not have a 
mathematical formula. However, to interpret the correlation step as being different from the 
mathematical formula would allow a competent drafter to avoid the limitations of Gottschalk by 
translating the mathematical formula into a series of steps in plain English. See In re Application of 
Richman, 563 F.2d 1026, 1030 (C.C.P.A. 1977); Diamond v. Diehr, 450 U.S. 175, 192 (1980). 
174 Parker v. Hook, 437 U.S. 584, 593 (1978). 
175 1d. 
176 1d. at 593 n.15. 
177 Id. at 593. 
19
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allow one to exclude others from its enjoyment. 178 The Court also 
emphasized that "patentable subject matter must be new[] [and] not 
merely heretofore unknown.,,179 
The correlation of an elevated total homocysteine concentration 
with a vitamin B deficiency is a law of nature. 180 The relationship 
between total homocysteine and a· vitamin B deficiency has always 
existed in human beings, long before LabCorp's important discovery)81 
The process of regulating the production of homocysteine based on the 
amount of vitamin B is part of a natural process in mammals. 182 Thus, 
LabCorp should not have the right to exclude others from using the 
natural phenomenon of an elevated total homocysteine concentration 
correlating to a vitamin B deficiency merely because its patent assignors 
were the first to discover such a relationship in nature. 183 
3. Claim 13 Does Not Entail a Physical Transformation of Matter 
Necessary to Satisfy 35 U.S.c. § 101 
The Court in Diehr held that if "a claim containing a mathematical 
formula ... perform[s] a function which the patent laws were designed to 
protect (e. g., transforming or reducing an article to a different state or 
thing), then the claim satisfies the requirements of § 101.,,184 In Diehr, 
the patentee claimed an improved process for molding rubber that used a 
mathematical equation known as the Arrhenius equation. 185The Court 
found that the process claim comprised several steps for molding rubber 
and thus did not wholly preempt all uses of the Arrhenius equation. 186 
The Court found that the Arrhenius equation was applied as a tool 
for improving the process of molding rubber. 187 The Court noted that the 
claim described a complete and detailed step-by-step process "beginning 
with the loading of a mold with raw, uncured rubber and ending with the 
178 [d. (citing P. Rosenberg, Patent Law Fundamentals, § 4, p. 13 (1975)). 
179 Flook, 437 U.S. at 593. 
ISO See Brief for Petitioner at 21, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. 
Ct. 2921 (2006) (No. 04-067), available at 2005 WL 3543099. 
181 See id.; Flook, 437 U.S. at 593. 
182 See Brief for Petitioner at 21, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. 
Ct. 2921 (2006) (No. 04-067), available at 2005 WL 3543099. 
183 See id. 
184 Diamond v. Diehr, 450 U.S. 175, 192 (1980). 
185 [d. at 177-179. 
186 /d. at 187. The opinion suggests that the Arrhenius equation could still be used in the 
process of curing rubber, but not in the same way as claimed by the patentee. [d. 
187 Diehr, 450 U.S. at 177-178. 
20
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eventual opening of the press at the conclusion of the cure.,,188 The 
Court justified the patentability of the claim because the process was an 
industrial process for physically producing an article that had historically 
been eligible to receive patent protection. 189 Because the process claim 
described the physical transformation of raw, uncured rubber to a 
different state, the Court held that the claim satisfied the requirement of 
35 V.S.c. § 101. 190 
The Court accepted the petitioner's definition of a mathematical 
formula, which is "a set of rules that leads [to] and assures development 
of a desired output from a given input.,,191 In Diehr, the input was a 
physical article, the raw, uncured rubber that goes into the mold, and the 
output was a precision-molded rubber part.192 Analogously, for Claim 
13, the input is the total homocysteine concentration, and the output is 
the knowledge of whether there is a presence or absence of a vitamin B 
deficiency. The total homocysteine concentration is a number and not a 
physical article. 193 Therefore, Claim 13 does not have a transformation 
or reduction of a physical article for satisfying 35 U.S.c. § 101 as 
construed by Diehr.194 
Metabolite Labs argued that Claim 13 does include a physical 
transformation of homocysteine in blood and should therefore be 
patentable subject matter based on Diehr. 195 Metabolite Labs supported 
the argument by noting that the written description of the '658 patent 
described a chemical process for transforming homocysteine into a 
different state for enabling the measurement with an instrument. 196 The 
chemical homocysteine may be construed as a physical article because it 
is a tangible matter. 197 However, the express language of Claim 13 does 
not include any limitations that describe a transformation of 
homocysteine itself. 198 Claim 13 merely states "assaying a body fluid" 
without stating any limitations for describing how to perform the 
188 [d. at 184. 
189 [d. 
190 [d. at 184, 192-93. 
191 See id. 
192 See id. at 177. 
193 Cf id. at 186 (discussing how the "alarm limit [was] simply a number" in Flook); see also 
Parker v. Rook, 437 U.S. 584, 586 (1978). 
194 Diehr, 450 U.S. at 192. 
195 Brief for Respondent at 33-35, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 
S. Ct. 2921 (2006) (No. 04-067). 
196 See id. 
197 [d. 
198 Brief for Petitioner at 27, Lab. Corp. of Am. Holdings v. Metabolite Labs .• Inc .• 126 S. Ct. 
2921 (2006) (No. 04-067). available at 2005 WL 3543099. 
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assay.l99 Because the Federal Circuit construed Claim 13 broadly to 
include any method of measuring total homocysteine, the measuring step 
should cover an assay that is either transformative or non-
transformative. 2°O For there to be a finding that Claim 13 included a 
transformation of blood, the claim must impermissibly read in a 
limitation from the specification. 201 Therefore, Claim 13 should not be 
construed to include a physical transformation of homocysteine, and thus 
it cannot satisfy 35 U.S.c. § 101 based on the holding of Diehr.202 
4. Claim 13 Does Not Contain a Process the Patent Laws Were 
Designed to Protect 
In a subsequent case, the Federal Circuit interpreted the use of 
"e.g." in Diehr to mean that the process does not necessarily have to be a 
transformation or reduction of an article to a different state or thing. 203 
Thus, the court of appeals concluded that a method claim that does not 
include a physical transformation can still be patentable under certain 
circumstances.204 In Diehr, the Court vaguely deemed a process to be 
patentable if it is "performing a function which the patent laws were 
designed to protect. ,,205 Because the transformation or reduction of a 
physical article is absent in Claim 13, the process claim must next be 
analyzed to determine whether it is a process that "patent laws were 
designed to protect" for qualifying as statutory subject matter under 35 
U.S.c. § 101.206 
A method of detecting a disease, such as a vitamin B deficiency, is 
the practice of medicine. 207 Patents that exclude physicians from 
performing new and useful medical methods for treating sick patients, 
independent of a particular type of instrument, have long been 
199 !d. 
200 If a future inventor were to discover a new method of measuring total homocysteine in 
blood without adding reagent chemicals, Claim 13 would still cover the new measuring method. See 
Brief for Petitioner at 27, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 
(2006) (No. 04-067), available at 2005 WL 3543099. 
201 See Brief for Petitioner at 27, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. 
Ct. 2921 (2006) (No. 04-067), available at 2005 WL 3543099. 
202 See Diamond v. Diehr, 450 U.S. 175, 192 (1980). 
203 AT&T Corp. v. Excel Commc'ns, Inc., 172 F.3d 1352, 1358-59 (Fed. Cir. 1999). 
204 [d. 
205 Diehr, 450 U.S. at 192; Excel, 172 F.3d at 1358-59. 
206 Excel, 172 F.3d at 1358-59. 
2(J/ See Brief Amicus Curiae of AARP In Support of Petitioner at 9-10, Lab. Corp. of Am. 
Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067). 
22
Golden Gate University Law Review, Vol. 38, Iss. 1 [2007], Art. 5
http://digitalcommons.law.ggu.edu/ggulrev/vol38/iss1/5
2007] PATENTING A DIAGNOSIS 161 
controversia1.208 In 1996, Congress enacted 35 U.S.c. § 287(c) to protect 
physicians from being liable for patent infringement that occurs during 
the performance of a medical activity.209 Thus, a physician who is a 
direct infringer of a method-of-diagnosis patent would not be liable to 
the patentee.210 In such a situation, the patent law (Le., 35 U.S.c. § 
287(c» was designed to protect the physician from liability for direct 
infringement of the process claim. 211 Extrapolating Congress's reasoning 
in enacting 35 U.S.C. § 287(c), a medical diagnostic claim would not be 
a traditional type of claim that "patent laws were designed to protect.,,212 
5. Claim 13 Does Have a Useful, Tangible, and Concrete Result But 
Still Does Not Satisfy 35 u.s.c. § 101 
Metabolite Labs argued that the process in Claim 13 produced a 
useful, tangible, and concrete result and should therefore be patentable 
subject matter under 35 U.S.c. § 101.213 Metabolite Labs noted that 
Claim 13 can be used to diagnose a person with a vitamin B deficiency, 
making it possible to prevent a potentially dangerous medical 
condition,214 the output of which is a useful, tangible, and concrete 
result. 215 
As noted above, in State Street Bank, the Federal Circuit held that a 
process claim without a physical transformation of matter could still be 
patentable subject matter so long as the result was useful, tangible, and 
concrete. 216 However, a process claim still cannot be used to patent a 
208 Morton v. N.Y. Eye Infinnary, 17 F. Cas. 879 (C.C.S.D.N.Y. I 862)DoNALD S. CHISUM, I-
I CHISUM ON PATENTS § 1.03[3] (2007). 
209 H.R. CONF. REp. No. 104-863, at 852-55 (1996); Brief Amicus Curiae of AARP In 
Support of Petitioner at 9-10, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 
(2006) (No. 04-067); Todd Martin, Patentability of Methods of Medical Treatment: A Comparative 
Study, 82 J. PAT. & TRADEMARK OFF. Soc'Y 381 (2000). 
2\0 This assumes that a physician's order of an assay would constitute a "performance of a 
medical ... procedure on a body" under 35 V.S.c. § 287(c). Brief Amicus Curiae of AARP In 
Support of Petitioner at 9-10, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 
(2006) (No. 04-067). As a side note, 35 V.S.c. § 287(c) does not apply to LabCorp because the 
'658 patent was filed on November 20, 1986, before the enactment of the statute. Id. at 9. 
211 Brief Amicus Curiae of AARP In Support of Petitioner at 9-10, Lab. Corp. of Am. 
Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067). 
212 See id.; Act of Sept. 30,1996, Pub. L. No. 104-208, 110 Stat. 3009-67-68. 
213 Brief for Respondents at 36, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. 
Ct. 2921 (2006) (No. 04-067), available at 2006 WL 303905 (citing State Street Bank & Trust Co. v. 
Signature Fin. Group, 149 F.3d 1368, 1373, 1375 (Fed. Cir. 1998)). 
214 1d. 
215 1d. 
216 State Street Bank, 149 F.3d at 1373. Justice Breyer's dissenting opinion in LabCorp could 
be interpreted as a hint that he and at least two other Justices would overrule State Street Bank. 
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law of nature, according to the Court in Diehr. 217 Thus, assuming that 
the Federal Circuit's holding in State Street Bank does not conflict with 
the Supreme Court's holding in Diehr, a process claim can be patentable 
if (1) the claim does not constitute an attempt to patent a law of nature 
and (2) the process provides a useful, concrete, and tangible result. 218 
However, as discussed above, Claim 13 of the '658 patent is a law 
of nature. 219 Therefore, Claim'13 cannot be patentable subject matter 
under 35 U.S.c. § 101, even though the process provides a useful, 
tangible, and concrete result.22o 
B. THE FEDERAL CIRCUIT'S INTERPRETATION OF CLAIM 13's SCOPE 
WAS Too BROAD 
In Metabolite Labs, the Federal Circuit broadly construed Claim 13 
so that both physicians and the reference laboratory (i.e., LabCorp) 
infringed.221 The court affIrmed the jury's finding that LabCorp had 
induced infringement and that physicians had directly infringed. 222 A 
negative consequence of the Federal Circuit's holding is that a physician 
can now directly infringe a patent while simply practicing medicine. 223 
Further, a reference laboratory's publication that generally describes the 
best practices in health care for detecting a deficiency in vitamin B can 
now be construed as an inducement to infringe. 224 
Justice Breyer noted that State Street Bank does say that "a process is patentable if it produces a 
'useful, concrete, and tangible result.' But this Court has never made such a statement and, if taken 
literally, the statement would cover instances where this Court has held the contrary." Lab. Corp. of 
Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 2921, 2928 (2006) (Breyer, J., 
dissenting) . 
217 Diamond v. Diehr, 450 U.S. 175, 185 (1980). 
218 See State Street Bank, 149 F.3d at 1373; see also Diehr, 450 U.S. at 185. 
219 See supra notes 174-183 and accompanying text. 
220 See State Street Bank, 149 F.3d at 1373; see also Diehr, 450 U.S. at 185. 
221 Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1361-65 (Fed. Cir. 
2004). 
222 [d. at 1364-65. 
223 Brief for the American Medical Association, the American College of Medical Genetics, 
the American College of Obstetricians and Gynecologists, the Association for Molecular Pathology, 
the Association of American Medical Colleges, and the College of American Pathologists as Amici 
Curiae in Support of Petitioner at 13-15, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 
S. Ct. 2921 (2006) (No. 04-067). 
224 Brief of the American 'Clinical Laboratory Association as Amicus Curiae in Support of 
Petitioner at 12-14, Lab. Corp. of Am. Holdings v. Metabolite Labs" Inc" 126 S. Ct. 2921 (2006) 
(No. 04-067). 
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1. Direct Infringement by Physicians 
The Federal Circuit's holding that physicians directly infringed was 
a surprising result. 225 Traditionally, direct infringement of a method 
claim requires that a single entity perform all of the steps. 226 Thus, a 
physician would have to perform the assaying step and the correlating 
step to support a finding of direct infringement.227 Technically, 
physicians did not perform the assay step, which should have prevented a 
finding of direct infringement. 228 The assaying step was performed at 
LabCorp, where the blood sample was mixed with reagent chemicals and 
processed with a laboratory instrument to obtain a total homocysteine 
concentration.229 
The Federal Circuit inexplicably broadened the assaying step to also 
include the ordering of an assay by a physician.23o Based on the plain 
language of Claim 13, the Federal Circuit has therefore appeared to 
establish an agency relationship between the physician and LabCorp to 
find that the physician effectively peiformed the assaying step.231 This 
was not altogether unprecedented. Some courts have held that direct 
infringement can be found when an independent contractor or agent is 
used to perform at least one of the steps of a method patent for 
manufacturing an article. 232 More recently, some courts have loosened 
the rule for direct infringement so long as there is "some connection" 
between the two parties performing the method claim. 233 
The Federal Circuit found that physicians performed the correlation 
225 See DONALD S. CHISUM, 5-16 CHISUM ON PATENTS sUPP. to § 16.02[6][a] (2007). 
226 See Mark A. Lemley, Inducing Patent Infringement, 39 V.c. DAVIS L. REV. 225, 226 
(2005). 
227 See id. 
228 See Mobil Oil Corp. v. Filtrol Corp., 501 F.2d 282,291-92 (9th Cir. 1974) (noting that it 
was questionable "whether a method claim can be infringed when two separate entities perform 
different operations and neither has control of the other's activities"); CHISUM, supra note 208, § 
16.02[6][a] ( "A thorny problem arises when different persons successfully perform the steps of a 
patented process."). 
229 See Brief for Amicus Curiae Perlegen Sciences, Inc. and Mohr, David Ventures in Support 
of Respondents at 8, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) 
(No. 04-067). 
230 Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1364 (Fed. Cir. 
2004). 
231 See CHISUM, supra note 225. 
232 E.g., Crowell v. Baker Oil Tools, Inc., 143 F.2d 1003, 1004 (9th Cir. 1944). 
233 Faroudja Labs., Inc. v. Dwin Electronics, Inc., No. 97-20010 SW, 1999 WL 111788, at *5 
(N.D. Cal. Feb. 24,1999) (citations omitted); E.I. DuPont De Nemours & Co. v. Monsanto Co., 903 
F. Supp. 680, 735 (D. DeI.l995), affd, 92 F.3d 1208 (Fed. Cir. 1996). 
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step, based on indirect evidence. 234 For this case, direct evidence would 
probably not be available unless physicians admitted to performing the 
correlation step in their minds. As one inventor testified, "[I]t would be 
malpractice for a [physician] to receive a total homocysteine assay 
without determining a [vitamin B] deficiency.'.z35 The court found that 
this supported the theory that physicians had performed the correlation 
step when merely ordering an assay.236 
Thus, a physician must now elect either to perform the mental step 
of correlating a total homocysteine concentration with a vitamin B 
deficiency or to commit malpractice. This leads to the absurd outcome 
that a physician should have an irresistible impulse to think about a 
vitamin B deficiency every time a total homocysteine assay is ordered 
and therefore infringe Claim 13 of the '658 patent. Using this logic, the 
mere ordering of a total homocysteine test by a physician will necessarily 
result in a direct infringement.237 Even if a physician intends to correlate 
the total homocysteine concentration with a cardiac disease, the 
physician must additionally perform a correlation to a vitamin B 
deficiency too, and therefore infringe the Claim 13 of the '658 patent. 238 
Therefore, based on the broad construction, a physician cannot avoid 
performing the correlation step and thus infringes Claim 13 of the '658 
patent when ordering a total homocysteine assay for the purpose of 
diagnosing a cardiac disease. 239 
In summary, based on the holding of Metabolite Labs, physicians 
can directly infringe a method-of-diagnosis claim by merely ordering an 
assay and thinking about it.240 Such a broad interpretation will inhibit 
both the practice of medicine and research into new or improved medical 
assays.241 Therefore, the rate of innovation in discovering new and better 
medical assays will likely decrease because of the increased possibility 
of patent infringement based on the holding of Metabolite Labs. 
234 Metabolite Labs, 370 F.3d at 1364-65. 
235 [d. at 1364. 
236 See id. 
237 Brief for Petitioner at 29, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 
2921 (2006) (No. 04-067), available at 2005 WL 3543099. 
238 [d. at 26; see Brief of the American Heart Association as Amicus Curiae in Support of 
Petitioner at 24, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 
04-067). It should be noted that there is strong interest in using the total homocysteine assay for 
diagnosing and treating cardiovascular disease. [d. at 18-19. 
239 See Brief of the American Heart Association as Amicus Curiae in Support of Petitioner at 
24, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067). 
240 See Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 2921, 
2927 (2006) (Breyer, J., dissenting). 
241 See id. at 2922. 
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2. LabCorp's Liability for Inducement to Infringe 
The Federal Circuit affirmed the jury's finding that LabCorp 
induced infringement because of its published article, which taught that 
elevated concentrations of total homocysteine can be correlated to a 
deficiency of vitamin B.242 In other words, LabCorp was found liable for 
infringement by publishing sound medical advice for helping patients 
and saving their lives. 243 LabCorp had merely published information 
regarding the diagnosis and treatment of a vitamin B deficiency,244 which 
was already published in a medical journat245 and in a patent 
specification. 246 With the Federal Circuit's decision, the '658 patent 
essentially enjoins people from communicating information needed to 
enable better medical treatment. 247 
Under the Federal Circuit's reasoning, anyone, not just a medical 
reference laboratory like LabCorp, who publishes information stating the 
relationship between total homocysteine and a deficiency of vitamin B 
may be found liable for inducement to infringe Claim 13. Such a broad 
reading of medical diagnostic patents could have a chilling effect on free 
speech in terms of communicating good medical advice or the practice of 
medicine. 248 In general, a decrease in the free exchange of information 
will also have an effect on innovation in the area of developing new and 
improved medical assays.z49 Free communication of ideas generally 
promotes research and the development of inventions. 25o "[T]he ultimate 
goal of the patent system is to bring new designs and technologies into 
242 See Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1365 (Fed. Cir. 
2004). 
243 See Brief Amicus Curiae of AARP In Support of Petitioner at 12-14, Lab. Corp. of Am. 
Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067). 
244 See Metabolite Labs, 370 F.3d at 1365. 
245 John Lindenbaum, M.D., Edward B. Healton, M.D., David G. Savage, M.D., John C.M. 
Brust, M.D., Thomas J. Garrett, M.D., Elaine R. Podell, B.A., Paul D. Marcell, B.S., Sally P. 
Stabler, M.D., & Robert H. Allen, M.D., Neuropsychiatric Disorders Caused by Cobalamin 
Deficiency in the Absence of Anemia or Macrocytosis, 318 NEW ENGLAND JOURNAL OF MEDICINE 
1720-28 (June 30, 1988), available at 2005 WL 3939546, at *211. 
246 U.S. Patent No. 4,940,658 (issued July 10, 1990). 
247 See Brief Amicus Curiae of AARP In Support of Petitioner at 12-14, Lab. Corp. of Am. 
Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067). 
248 Cf Washington Legal Found. v. Henney, 202 F.3d 331, 335-336 (D.C. Cir. 2000) (noting 
that a First Amendment right existed to provide published articles to physicians about a drug's 
benefits without violating the Food and Drug Administration Modernization Act (FDAMA». Later, 
the FDA asserted that an amended version of the FDAMA did not prohibit the dissemination of 
published articles causing the constitutional issue to be moot. ld. at 334. 
249 See W. Fritz Fasse, The Muddy Metaphysics of Joint lnventorship: Cleaning Up After the 
1984 Amendments to 35 U.S.c. § 116,5 HARV. J. LAW & TECH. 153, 159-60 & n.37 (1992). 
250 See id. 
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the public domain through [publication].,,251 
Medical researchers must now be careful about their research 
activities and their publications. Based on Madey v. Duke University, 
even academic researchers can be liable for infringement of patents when 
performing basic research with a potential profit motive.252 Any 
publication that can be construed as sound medical advice in diagnosing 
a disease can now be potentially used as a basis for inducement to 
infringe a patent.253 In view of Metabolite Labs, a patent can be a prior 
restraint that inhibits publication of scientific information. Moving 
forward, a researcher will now have to contemplate searching prior 
patents before publishing because the researcher could potentially be 
liable for inducement to infringe if the publication happens to teach a 
process that infringes a patent. 254 
Ironically, LabCorp would likely have been better off not publishing 
the article and waiting for physicians to learn about the beneficial use of 
the assay through other means. For example, an academic researcher or 
a medical professional society255 could have published the benefits of the 
'658 patent to educate physicians about total homocysteine 
measurements causing physicians to order the assay from LabCorp. 
Based on the holding of Warner-Lambert v. Apotex, LabCorp's mere 
knowledge alone that physicians would likely infringe the '658 patent 
was not enough for a finding of inducement to infringe.256 . Therefore, 
LabCorp could have avoided an inducement to infringe by not publishing 
the article and simply selling the assay to physicians who learned about 
the benefits through other means.257 
251 Bonito Boats v. Thunder Craft Boats, 489 U.S. 141, 151 (1989). 
252 Madey v. Duke Univ., 307 F.3d 1351, 1362 & n.7 (Fed. Cir. 2002) ("[Nlon-profit status of 
the user is not determinative" for determining if experimental use exception applies because non-
profit institutions can have "an aggressive patent licensing program from which it derives a not 
insubstantial revenue stream"). 
253 See Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1365 (Fed. Cir. 
2004). 
254 See Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 2921, 
2928-29 (2006) (Breyer, J., dissenting). 
255 Examples of medical professional societies are the American Medical Association, 
American Association of Clinical Chemistry, and American Heart Association. 
256Wamer-Lambert Co. v. Apotex Corp., 316 F.3d 1348, 1363 (Fed. Cir. 2003) (citing 
Manville Sales Corp. v. Paramount Sys., Inc., 917 F.2d 544, 553 (Fed.Cir.1990)). Apotex sought to 
market a generic drug that could be used to infringe a new method-of-use patent owned by Wamer-
Lambert. [d. at 1352. However, the Federal Circuit found no inducement to infringe by Apotex 
because it did not seek to market the drug for the patented use. See id. at 1365. The fact that Apotex 
probably knew that the majority of the generic drug sales would be used for the infringing use was 
not enough to establish liability. [d. 
257 See Warner-Lambert, 316 F.3d at 1363. 
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C. PUBLIC POLICY CONSIDERATIONS 
1. Claim 13 Stifles Future Development 
In the past, the United States Supreme Court has used public policy 
to invalidate a broad patent claim that essentially preempts the field. 258 It 
is instructive to examine an early patent law case. Samuel Morse, who 
invented the telegraph, had obtained a broad claim directed to any 
method of using electromagnetism, independent of his device, for 
transmitting messages over any distance. 259 The Court found that the 
broad claim would preempt any use of the natural phenomenon known as 
electromagnetism for transmitting messages. 260 Because the claim gave 
an exclusive right to every improvement in which electromagnetism was 
used for transmitting a message, the Court invalidated this claim as being 
too broad.261 
The Court noted that allowing Morse's broad claim would inhibit 
improvements in the field of using electromagnetism for transmitting 
messages and that the public would be deprived of the potential 
benefit. 262 The Court speculated that a future inventor might invent an 
improved method for transmitting messages using electromagnetism 
without using any part of the process or combination set forth in the 
Morse patent.263 According to the Court, such improvements could be an 
improved machine that is less complicated, more robust, less expensive 
to build, and less expensive to operate.264 The Court wanted to prevent 
Morse from having patent rights to all future improvements if he did not 
contribute to them. 265 The Court noted that allowing Morse's broad 
claim would prevent a future inventor from using the improved machine 
unless Morse provided his permission.266 In summary, the Court held 
Morse's broad generic claim invalid so that the public could benefit from 
improvements by entities other than Morse. 267 
Morse's claim covering any use of electromagnetism is analogous 
258 See O'Reilly v. Morse, 56 U.S. 62, 113 (1854). 
259 See id. at 112. 
260 Id. at 112-113. 




265 CHISUM, supra note 208, § 1.03[2][c]; see Morse, 56 U.S. at 113. 
266 Morse, 56 U.S. at 113. 
267 1d. 
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to Metabolite's claim covering any method of measuring total 
h ·268 Th fl . f .. omocysteme. e use 0 e ectromagnetlsm or transffilttmg a 
message necessarily included a step for measuring electromagnetism. 269 
Additionally, Claim 13 covers unpatented methods and future methods 
for measuring total homocysteine concentration that is analogous to 
Morse's broad claim that preempted the use of electromagnetism. 270 
Thus, Claim 13 would cover every improvement to the method of 
measuring total homocysteine even if Metabolite Labs does not 
contribute to the improvements, which is exactly the same situation that 
. d' M 271 eXlste morse. 
The '658 patent has already prevented the public from benefiting 
from improvements to the total homocysteine assay. Not surprisingly, 
one inventor did improve the method of measuring total homocysteine 
after the original discovery cited in the '658 patent. 272 Abbott 
Laboratories commercialized an improved assay, which required only a 
few minutes as opposed to upwards of eighteen hours with the 
Metabolite method. 273 Additionally, the Abbott assay was less labor-
intensive and therefore less expensive than the Metabolite assay.274 The 
public could potentially benefit from the Abbott assay in the form of 
reduced assay cost and a reduced turnaround time.275 However, the 
jury's finding that a physician's use of Abbott's improved assay 
infringed Claim 13 was upheld by the Federal Circuit.276 Thus, 
Metabolite Labs can block the use of the improved assay even though it 
did not contribute to the improvement. In summary, Claim 13 should be 
invalidated based on the public policy reasons described in Morse; 
otherwise the public cannot benefit from improvements to the assay.277 
268 Compare Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1358-59 
(Fed. Cir. 2004) with Morse, 56 U.S. at 112. 
269 See Morse, 56 U.S. at 112-13. The measurement step occurred when the armature moved 
in response to the presence or absence of a sufficient amount of electromagnetism to form a dot or a 
dash. 
270 Compare Metabolite Labs, 370 F.3d at 1358-59, with Morse, 56 U.S. at 112. 
271 Morse, 56 U.S. at 112-13. 
272 Brief for Petitioner at 9, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 
2921 (2006) (No. 04-067), available at 2005 WL 3543099. 
273 [d. 
274 [d. 
275 In general, a short test time has a big advantage because a physician can communicate the 
results to the patient faster. Additionally, the physician can start treatment for the vitamin B 
deficiency much sooner. 
276 See Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1365 (Fed. Cir. 
2004). 
m See O'Reilly v. Morse, 56 U.S. 62,112-13 (1854). 
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2. Broad Method Claims Will Inhibit Future Research Needed by the 
Public-An Example Is a Genetic Test for Breast Cancer 
169 
There is a great need to develop new and improved medical assays 
to help identify diseases and to provide better treatment options to the 
patient.278 In particular, there has been an explosion in research activity 
for genetic tests.279 New and better genetic tests may allow earlier and 
more accurate diagnosis of diseases, better prediction of whether a 
patient will be diagnosed with a particular disease in the future, 
personalized drugs that are adapted for maximal efficacy based on a 
person's genetic sequence, and faster development cycles for drug 
development. 280 Allowing broad diagnostic claims, as did the court of 
appeals in Metabolite Labs,281 will have a chilling effect on the 
development of better laboratory assays.282 The following illustrates the 
chilling effect on future research by describing an example of a genetic 
test that has a need for improvement but is limited because of broad 
method claims. 
Myriad Genetics offers a genetic test that predicts whether a person 
has a strong likelihood of getting breast cancer. 283 If a person has a 
mutated BRCAI or BRCA2 gene, then the person has a thirty-six to 
eighty-five percent chance of getting breast cancer?84 In comparison, 
about thirteen percent of the general population will be diagnosed with 
breast cancer.285 The discovery of a gene that predicts an increased 
likelihood of getting breast cancer was a pioneering breakthrough. 286 
From the patient's viewpoint, however, the BRCAI and BRCA2 test 
278 See Brief of the American Clinical Laboratory Association as Amicus Curiae in Support of 
Petitioner at 8-13, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) 
(No. 04-067). 
279 See Brief for Amicus Curiae Affymetrix, Inc. and Professor John H. Barton in Support of 
Petitioner at 15-20, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) 
(No. 04-067). 
280 See id. 
281 Metabolite Labs, 370 F.3d at 1363-64. 
282 See Brief for Amicus Curiae Affymetrix, Inc. and Professor John H. Barton in Support of 
Petitioner at 20, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 
04-067). 
283 Melissa E. Horn, Note, DNA Patenting and Access to Healthcare: Achieving the Balance 
Among Competing Interests, 50 CLEV. ST. L. REv. 253, 269 (2002). 
284 National Cancer Institute: U.S. National Institute of Health, Genetic Testing for BRCAI 
and BRCA2, http://www.nci.nih.gov/cancertopics/factsheetlRiskIBRCA (last visited Sept. 25,2006). 
285 Id. 
286 See Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The 
Anticommons in Biomedical Research, 280 SCIENCE 698, 699 (1998). 
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may cause more confusion than it is worth. 287 For instance, even if the 
mutation is detected, there is up to a sixty-four percent chance that the 
patient will not get breast cancer.288 In other words, a patient who was 
diagnosed as having the BRCAI or BRCA2 gene will have to deal with 
the stress of possibly getting breast cancer for the rest of his or her ·life, 
even though there is still a significant chance (up to sixty-four percent) 
that breast cancer will not occur.289 
A person who has a mutated BRCAl or BRCA2 gene will struggle 
with whether to take preemptive action to improve his or her outcome. 290 
Although the person may be a prime candidate for considering an 
experimental drug291 or procedure292 to prevent the onset of breast 
cancer, there will be a risk of serious side effects.293 To further 
complicate matters, as many as sixty-four out of a hundred people with 
the gene mutation will not get the disease and will thus be treated 
unnecessarily.294 Therefore, although the BRCAI and BRCA2 test for 
breast cancer shows great promise, there is a clear need to improve the 
test's predictive power. 295 
For entities other than Myriad Genetics, there is little incentive to 
develop a better multiple gene test that uses BRCAI or BRCA2, because 
such a test will infringe one of Myriad Genetics' patents.296 Myriad 
287 See David E. Adelman, A Fallacy of the Commons in Biotech Patent Policy, 20 BERKELEY 
TECH. L.J. 985, 1005-06 (2005). 
288 National Cancer Institute: U.S. National Institute of Health, Genetic Testing for BRCAI 
and BRCA2, http://www.nci.nih.gov/cancertopics/factsheetiRiskIBRCA (last visited Sept. 25,2006). 
289 Id. 
290 See id. 
291 An example of an experimental drug for preventing breast cancer is tamoxifen. National 
Cancer Institute: U.S. National Institute of Health, Genetic Testing for BRCAI and BRCA2, 
http://www.nci.nih.gov/cancertopicslfactsheetiRiskIBRCA (last visited Sept. 25,2006). 
292 As an extreme example of an experimental procedure, some women with the gene 
mutation have elected to remove their breast tissue (i.e., mastectomy) to prevent the possible 
occurrence of breast cancer. National Cancer Institute: U.S. National Institute of Health, Genetic 
Testing for BRCAI and BRCA2, http://www.nci.nih.gov/cancertopicslfactsheetlRiskIBRCA (last 
visited Sept. 25, 2006). 
293 An example of an experimental drug that caused serious side-effects was Prempro 
(hormone replacement therapy). Biospace.com, 
http://www.biospace.com!news_story.aspx?StoryID=8486 (last visited Dec. 31,2006). A large scale 
NIH study showed that Prempro actually increased the risk of breast cancer as well as the risk of 
other diseases such as heart disease, stroke, and dementia. Id. Unfortunately, a significant number 
of women used Prempro and, in the process, helped Wyeth generate about one billion dollars in sales 
for the year 200 I. Id. 
294 National Cancer ,Institute: U.S. National Institute of Health, Genetic Testing for BRCAI 
and BRCA2, http://www.nci.nih.gov/cancertopics/factsheetiRiskIBRCA (last visited Sept. 25,2006). 
295 See David E. Adelman, A Fallacy of the Commons.in Biotech Patent Policy, 20 BERKELEY 
TECH. LJ. 985,1005-06 (2005). 
296 See Melissa E. Horn, Note, DNA Patenting and Access to Healthcare: Achieving the 
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Genetics has a broad method claim that essentially patents a law of 
nature similar to Claim 13 of the '658 patent. 297 Any improved test that 
uses BRCAI or BRCA2 will require a license from Myriad Genetics. 298 
Assuming that Myriad Genetics would grant a reasonable license,299 the 
researcher would then be burdened with increased costs for developing 
the improved assay or risk being sued for patent infringement. 300 
Because research is a high-risk and costly investment, researchers will 
tend to avoid developing better assays that require a licensing agreement 
and look to develop new assays that are unencumbered by existing 
patents. 30 1 
Discovering a better breast-cancer-prediction assay in an expedited 
manner that uses multiple genes302 including either BRCA1, BRCA2, or 
a combination thereof is a very complicated problem that would likely 
require a large-scale effort using the world's best and brightest 
Balance Among Competing Interests, 50 CLEV. ST. L. REV. 253,264-267 (2002). 
297 Compare U.S. Patent No. 4,940,658 (issued July 10, 1990) (correlating an elevated level 
of total homocysteine with diagnosing a vitamin B deficiency) with U.S. Patent No. 5,709,999 
(issued Jan. 20, 1998) (correlating the presence of a particular gene mutation with the likelihood of 
developing breast cancer); Brief for Amicus Curiae Affymetrix, Inc. and Professor John H. Barton in 
Support of Petitioner at 18-20, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 
2921 (2006) (No. 04-067). 
298 See Jordan Paradise, European Opposition to Exclusive Control Over Predictive Breast 
Cancer Testing and the Inherent Implications for u.s. Patent lAw and Public Policy: A Case Study 
of the Myriad Genetics' BRCA Patent Controversy, 59 FOOD & DRUG LJ. 133, 149 (2004). 
299 Myriad Genetics has not granted an exclusive license to anyone for the breast cancer 
patents. Shan shan Zhang, Comment, High Tech lAw Institute Publications: Proposing Resolutions 
to the Insufficient Gene Patent System, 20 SANTA CLARA COMPUTER & HIGH TECH. L.J. 1139, 1159 
(2004). 
300 See Jordan Paradise, European Opposition to Exclusive Control Over Predictive Breast 
Cancer Testing and the Inherent Implications for u.s. Patent lAw and Public Policy: A Case Study 
of the Myriad Genetics' BRCA Patent Controversy, 59 FOOD & DRUG LJ. 133,149-50 (2004). The 
risk of being sued for patent infringement appears to be significant. Mildred K. Cho et aI., Effects of 
Patents and licenses on the Provision of Clinical Genetic Testing Services, Journal of Molecular 
Diagnostics, 25 JOURNAL OF MOLECULAR DIAGNOSTICS 3, 5 (2003), available at 
http://www.bioethics.upenn.edu/proglethicsgeneslpdflcho_etal_2003.pdf. A survey of laboratories 
performing genetic tests showed that sixty-five percent of the laboratories have been contacted by a 
patent holder regarding potential infringement. Id. In addition, about fifty percent of the survey 
participants decided not to develop or perform a genetic test specifically because of intellectual-
property considerations. Id. at 7. 
301 See Jordan Paradise, European Opposition to Exclusive Control Over Predictive Breast 
Cancer Testing and the Inherent Implications for u.s. Patent lAw and Public Policy: A Case Study 
of the Myriad Genetics' BRCA Patent Controversy, 59 FOOD & DRUG LJ. 133, 149-150 (2004). 
302 See Melissa E. Horn, Note, DNA Patenting and Access to Healthcare: Achieving the 
Balance Among Competing Interests, 50 CLEV. ST. L. REV. 253, 272-273 (2002). One logical 
possibility for improving the test's predictive power is to discover one or more genes that can be 
combined with either the BRCAI or BRCA2 gene. Id. The theory is that two genes (or more) are 
better than one for predicting a complicated disease such as breast cancer. See id. 
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researchers. 303 Because Myriad Genetics is only one company, it does 
not have sufficient resources to try all possible combinations of genes 
and strategies to improve the assay. As a result, Myriad Genetics may 
have an underutilized monopoly on a natural phenomenon that is an 
important piece for solving the breast-cancer-prediction puzzle.304 Thus, 
Myriad Genetics is likely slowing down the progress of improving the 
assay because of its broad patent position.305 
Myriad Genetics may have little financial incentive to incrementally 
improve its assay for breast cancer. Because Myriad Genetics can charge 
a relatively high fee for its test,306 it may not want to bother taking on the 
financial risk to incrementally improve its technology. Thus, Myriad 
Genetics may be able to make more money by simply selling the BRCAI 
and BRCA2 test until its patents expire, because of its broad patent 
pOSItion. To further complicate matters, Myriad Genetics may not be 
able to recoup its investment costs through increased sales by improving 
its test, because the current test may be too profitable. 307 
In summary, there is a need to incrementally improve diagnostic 
assays such as the BRCAI and BRCA2 test, but allowing patents with 
broad method claims will inhibit such improvements.308 With the breast-
cancer test, for example, more reliable laboratory tests will enable better 
treatments or at least enable more rational decisions about electing 
experimental treatments.309 The public has a need for better laboratory 
303 See David E. Adelman, A Fallacy of the Commons in Biotech Patent Policy, 20 
BERKELEY TECH. L.l. 985, 1006-1024 (2005). "[TJhe dichotomy between genetic-data production 
and invention creates an environment in which research opportunities are, as a practical matter, 
unbounded because they far exceed the capacities of the scientific community." Id. at 1017. 
3()4 See Melissa E. Horn, Note, DNA Patenting and Access to Healthcare: Achieving the 
Balance Among Competing Interests, 50 CLEV. ST. L. REv. 253,270 (2002). 
305 See id. at 266. This situation has been referred to as a "tragedy of the anticommons," 
where a resource is underused "because too many people are excluded from using the resource," as 
is the case when a natural phenomenon is patented. See id. 
306 See Shanshan Zhang, Comment, High Tech Law Institute Publications: Proposing 
Resolutions to the Insufficient Gene Patent System, 20 SANTA CLARA COMPUTER & HIGH TECH. L.l. 
1139, 1159 (2004). Myriad Genetics charges about $2700 per test that is performed exclusively at 
Myriad Genetics' laboratory in Utah. Id. at 1159-60. Therefore, all blood samples from around the 
world must be sent to only one laboratory in Utah to have a BRCAI or BRCA2 test performed. Id. 
307 See Shanshan Zhang, Comment, High Tech Law Institute Publications: Proposing 
Resolutions to the Insufficient Gene Patent System, 20 SANTA CLARA COMPUTER & HIGH TECH. L.J. 
1139, 1159 (2004). 
308 Melissa E. Horn, Note, DNA Patenting and Access to Healthcare: Achieving the Balance 
Among Competing Interests, 50 CLEv. ST. L. REv. 253,268 (2002). 
309 See National Cancer Institute: U.S. National Institute of Health, Genetic Testing for 
BRCAI and BRCA2, http://www.nci.nih.gov/cancertopicslfactsheetlRisklBRCA (last visited Sept. 
25,2006). 
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tests that can be used as a tool for improving healthcare.3lo There is a 
large number of diseases that could be potentially diagnosed and treated 
more effectively through improved diagnostic testing, such as 
Alzheimer's disease, rheumatoid arthritis, cardiovascular disease, 
diabetes, osteoporosis, schizophrenia, and autism. 311 However, 
researchers will not have an incentive to take on the risk of incrementally 
improving an assay if broad diagnostic claims are allowed to remain 
valid, even when there is a market-driven, unmet need for such an 
improvement. 312 
III. CONCLUSION 
The United States Supreme Court should have reversed the Federal 
Circuit's holding in Metabolite Labs.313 The method-of-diagnosis claim 
in Metabolite Labs is the equivalent of a mathematical formula that 
wholly preempts a law of nature. 314 Further, the method-of-diagnosis 
claim in Metabolite Labs does not entail a physical transformation of 
matter to satisfy 35 U.s.c. § 101 based on Diehr.315 Claim 13 of the 
'658 patent does provide a useful, tangible, and concrete result for 
diagnosing a medical disease, satisfying the requirements of State Street 
Bank,316 but it still does not satisfy 35 U.S.c. § 101, because Claim 13 is 
an attempt to patent a law of nature. The Federal Circuit affIrmed a 
construction of the method-of-diagnosis claim that is so broad that 
improvements to medical assays and healthcare will now be stifled. 317 
310 Brief for Amicus Curiae Affymetrix, Inc. and Professor John H. Barton in Support of 
Petitioner at 12-20, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) 
(No. 04-067). 
311 Brief for Amicus Curiae Perlegen Sciences, Inc. and Mohr, David Ventures in Support of 
Respondents at 21, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) 
(No. 04-067). 
312 See Melissa E. Horn, Note, DNA Patenting and Access to Healthcare: Achieving the 
Balance Among Competing Interests, 50 CLEV. ST. L. REV. 253,269 (2002). 
313 Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (Lab Corp) , 126 S. Ct. 2921 (2006); 
Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354 (Fed. Cir. 2004). 
314 See supra notes 174-183 and accompanying text. 
315 LabCorp, 126 S. Ct. at 2927 (Breyer, J., dissenting); Diamond v. Diehr, 450 U.S. 175, 192 
(1980). 
316 State Street Bank & Trust Co. v. Signature Fin. Group, 149 F.3d 1368, 1373 (Fed. Cir. 
1998). 
317 Metabolite Labs, 370 F.3d at 1358. 
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